Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nassir Marrouche

Clinical Cardiac Electrophysiology New Orleans, LA Medical Doctor

NPI 1881708295 CMS profile 175816

1415 Tulane Ave Fl 4, New Orleans, LA 70112

Open in the dashboard

General payments

$497,565

265 records reported · program years 2019–2025

Research payments

$10,796

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,096,201 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Nassir Marrouche of New Orleans, LA is reported in the CMS Open Payments database as having received $497,565 across 265 general payments and $10,796 in research payments paid to them. Separately, studies naming them as principal investigator received $11,096,201 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75,864 60
2024 General $62,976 62
2024 Research $5,700 2
2023 General $29,606 42
2022 General $36,008 17
2021 General $26,647 12
2020 General $78,005 17
2020 Research $2,371 2
2019 General $188,460 55
2019 Research $2,725 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nassir Marrouche
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Nassir Marrouche were reported at $75,864. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Nassir Marrouche Clinical Cardiac Electrophysiology median Middle half National median
2019 $188,460 $2,361 $585–$8,260 $163
2020 $78,005 $993 $247–$4,351 $114
2021 $26,647 $1,185 $326–$4,739 $132
2022 $36,008 $2,073 $554–$6,789 $149
2023 $29,606 $2,568 $759–$8,159 $160
2024 $62,976 $2,557 $703–$7,403 $164
2025 $75,864 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Preventice Services, LLC $135,000 5 payments
  2. Biosense Webster, Inc. $133,492 73 payments
  3. Biotronik Inc. $75,564 24 payments
  4. Medical Device Business Services, Inc. $39,490 9 payments
  5. Sanofi-Aventis U.S. LLC $32,492 13 payments
  6. Boston Scientific Corporation $28,625 47 payments
  7. E.R. Squibb & Sons, L.L.C. $9,594 6 payments
  8. Medtronic Vascular, Inc. $9,367 16 payments
  9. Siemens Medical Solutions USA, Inc. $9,188 12 payments
  10. Medtronic, Inc. $7,996 12 payments
  11. Other $16,756 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $297,888 37 payments
  2. Travel and Lodging $86,575 64 payments
  3. Grant $50,000 2 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $42,580 11 payments
  5. Food and Beverage $8,280 144 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $4,300 2 payments
  7. Honoraria $4,260 2 payments
  8. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,600 2 payments
  9. Education $83 1 payment
Products named General payments · program years 2019–2025
  1. Carto 3 $116,048 69 payments
  2. Carto 3 System $54,593 6 payments
  3. MULTAQ Cardiology/Vascular Diseases $16,999 9 payments
  4. BG Mini Plus $15,000 3 payments
  5. Arctic Front $4,819 10 payments
  6. MULTAQ Cardiovascular $3,297 2 payments
  7. ENSITE PRECISION $3,046 2 payments
  8. (9310) EPD KODEX Innovation $2,760 1 payment
  9. CLINICAL TRIAL PRODUCT $2,662 4 payments
  10. Thermocool SF $2,160 3 payments
  11. Other $14,754 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Janssen Scientific Affairs, LLC $5,700 2 payments
  2. Sanofi-Aventis U.S. LLC $5,096 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

55

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$38,627

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

80%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $23,470
Xarelto Rivaroxaban Brand 20 $14,950
Metoprolol Succinate Generic 11 $206

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$127,266

Medicare's payments for the services billed

Medicare patients

158

Average age 75

Services billed

586

71 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 54%
Arthritis 53%
Heart failure 40%
Diabetes 29%
Chronic kidney disease 29%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $48
$48 — —
ELIQUIS
  • PFIZER INC. $24
  • E.R. Squibb & Sons, L.L.C. $18
$41 24 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $34
$34 — —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $23
$23 — —
Ozempic
  • Novo Nordisk Inc $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record